Terns Pharmaceuticals, Inc.
TERNDelisted May 5, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831363
Terns Pharmaceuticals, Inc. was delisted on May 5, 2026; its insiders filed their last Form 4 on May 5, 2026; 317 institutions reported holding it in 13F filings for Q1 2026, worth $6.56B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q4 2025
Institutional positions in Terns Pharmaceuticals, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 248
- +107 vs. Q3 2025
- Shares held
- 122.6M
- +34.0M (+38.3%) vs. Q3 2025
- Total value
- $4.95B
- +$4.29B (+644.0%) vs. Q3 2025
- New holders
- 124
- 72 more added
- Sold out
- 17
- 42 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TERN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $75.4K |
| Q1 2026 | 317 | $6.56B |
| Q4 2025 | 248 | $4.95B |
| Q3 2025 | 141 | $665.7M |
| Q2 2025 | 130 | $310.0M |
| Q1 2025 | 138 | $229.4M |
| Q4 2024 | 157 | $477.2M |
| Q3 2024 | 156 | $663.1M |
| Q2 2024 | 126 | $446.7M |
| Q1 2024 | 112 | $414.8M |
| Q4 2023 | 103 | $412.7M |
| Q3 2023 | 93 | $310.4M |
| Q2 2023 | 103 | $505.0M |
| Q1 2023 | 79 | $630.2M |
| Q4 2022 | 65 | $506.2M |
| Q3 2022 | 45 | $178.1M |
| Q2 2022 | 42 | $36.5M |
| Q1 2022 | 44 | $50.0M |
| Q4 2021 | 37 | $116.7M |
| Q3 2021 | 34 | $174.3M |
| Q2 2021 | 36 | $203.8M |
| Q1 2021 | 42 | $393.7M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Terns Pharmaceuticals, Inc.; share changes are against Q3 2025.